- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00211055
A Study to Observe the Causes and Treatment of Anemia in Critically Ill Children
April 15, 2013 updated by: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
A Multicenter, Epidemiological, Observational Study of the Management of Anemia in Critically Ill Pediatric Patients
The purpose of this study is to determine the incidence of anemia and blood transfusions and management of these in critically ill children
Study Overview
Status
Completed
Conditions
Detailed Description
Critically ill patients admitted to the intensive care unit often have anemia from one or more of a number of possible causes including blood loss due to surgery or injury, frequent blood sampling, chronic diseases such as kidney failure or cancer or treatments being received, such as chemotherapy.
Although the common treatment for anemia is red blood cell transfusion, the current guidelines for blood transfusions for children are based on available information regarding transfusions in adults.
Since many characteristics specific to critically ill children may affect the way in which they respond to anemia and transfusion, additional information is needed to better define guidelines for the prevention and treatment of anemia in critically ill children.
This is a multi-center study to collect information regarding the management of anemia in critically ill children.
Information needed to evaluate anemia, blood loss and transfusions will be collected from the patients' hospital records.
No blood draws or procedures will be required by this survey and no medication will be supplied by the study Sponsor.
Each patient's treating physician will be responsible for all decisions regarding his/her clinical care and treatment during the study.
Approximately 1200 patients will be enrolled into this study, which is divided into 2 parts.
During part 1, at least 400 patients who are newly admitted to the Pediatric Intensive Care Unit (PICU) will be enrolled, regardless of their length of stay in the PICU.
During part 2, up to an additional 800 patients who are newly admitted into the PICU and have remained there for > = 48 hours at the time of entry into the study will be enrolled.
Information for each patient will be collected for up to 28 days or until time of discharge from the hospital or death of the patient, whichever occurs first.
Blood loss will be reported for each day the patient remains in the PICU; information regarding the treatment of anemia, including number and reasons for transfusions will be collected for a maximum of 28 days, regardless of the length of stay in the PICU.
Information collected at the time of discharge from the hospital will include date of discharge and whether or not the patient is receiving mechanical assistance to breathe.
Several possible hypotheses are being generated in this study: 1) Blood loss due to procedures and routine laboratory tests may be a major cause of anemia and transfusions in critically ill children; 2) Determining significant causes of anemia and blood transfusions in children will allow for better future treatment of anemia; and 3) Pediatric patients who receive blood transfusions have more days on a ventilator (a machine that helps patients who cannot breathe on their own), longer stays in the PICU and decreased organ function.
Since the study involves only collection of information, no treatment will be required by the Sponsor and no medication will be supplied by the Sponsor.
Study Type
Observational
Enrollment (Actual)
1201
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 17 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female patients aged 0 to 17 years
- During part 1 of this study, patients must be newly admitted to the Pediatric Intensive Care Unit (PICU) (regardless of stay)
- During part 2 of the study, patients must be newly admitted to the PICU and have stayed there for > = 48 hours
- Patients' legally acceptable representatives must have signed an informed consent
- Patients aged 7 years and above must give assent if or when they are physically capable
Exclusion Criteria:
- Premature infants (patients who were born at < = 37 weeks who are < 28 days old)
- Patients who have previously participated in this study
- Patients from a family unwilling to receive blood transfusions (for example for religious reasons)
- Patients who are participating in any other transfusion or blood-related research at the time of entry into the study or any time during the study
- Patients who are known to be pregnant (no pregnancy test will be performed in this study)
- Patients with known or suspected brain death
- Patients who have had a Pediatric Intensive Care Unit (PICU) stay of longer than 72 hours within the 7 days prior to entering the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2004
Study Completion (Actual)
March 1, 2005
Study Registration Dates
First Submitted
September 13, 2005
First Submitted That Met QC Criteria
September 13, 2005
First Posted (Estimate)
September 21, 2005
Study Record Updates
Last Update Posted (Estimate)
April 16, 2013
Last Update Submitted That Met QC Criteria
April 15, 2013
Last Verified
April 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR004396
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anemia
-
SanofiActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)United States, Austria, China, Denmark, Germany, Hungary, Italy, Spain, United Kingdom
-
SanofiTerminatedWarm Autoimmune Hemolytic Anemia (wAIHA)United Kingdom, Belgium, Netherlands, France, United States, Germany, Hungary, Italy
-
Hospital Universitario Dr. Jose E. GonzalezCompletedPernicious Anemia | Megaloblastic Anemia NosMexico
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingSevere Aplastic Anemia | Idiopathic Aplastic Anemia | Moderate Aplastic Anemia Requiring Transfusions
-
Abdelwahed, Mai Mahmoud Mohamed, M.D.UnknownAnemia During PregnancyEgypt
-
University of California, DavisInstituto Mexicano del Seguro Social; Thrasher Research Fund; Mexican National... and other collaboratorsCompleted
-
Incyte CorporationActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)Spain, United States, Austria, Belgium, Canada, France, Germany, Israel, Italy, Japan, Netherlands, Poland, United Kingdom
-
Peking Union Medical College HospitalRecruiting
-
Alexion PharmaceuticalsWithdrawnWarm Autoimmune Hemolytic AnemiaUnited States